Con­tend­ing for CD47 throne, Arch On­col­o­gy scores $50M as it ramps up PhI stud­ies

Arch On­col­o­gy, one of the old­er star­tups in a crop of im­muno-on­col­o­gy play­ers chas­ing af­ter the CD47 tar­get, has bagged $50 mil­lion to fu­el a long dri­ve in the clin­ic that re­cent­ly be­gan.

Some might re­mem­ber the com­pa­ny as Tioma Ther­a­peu­tics, break­ing out in 2016 with some years of pre­clin­i­cal work and in­vest­ments from Glax­o­SmithK­line, Roche and No­vo. A year lat­er, it re­named it­self to Arch On­col­o­gy and brought in new CEO Julie Cher­ring­ton to re­place John Dono­van in pur­suit of a “more high­ly dif­fer­en­ti­at­ed” com­pound.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER